Publications scientifiques

2660 PUBLICATIONS

ANNÉE

JOURNAL

PREMIER AUTEUR

TITRE

ANNÉE2027

JOURNALLung cancer (Amsterdam, Netherlands)

PREMIER AUTEURCho BC

TITREMORPHEUS-Lung: biomarkers and clinical response to atezolizumab + bevacizumab + stereotactic body radiotherapy in patients with metastatic non-small cell lung cancer.

ANNÉE2026

JOURNALOncoimmunology

PREMIER AUTEURLécuelle J

TITREDeep learning based on CD3 histological slides for prediction of colon cancer outcome: analysis of three international stage III colon cancer cohorts.

ANNÉE2026

JOURNALOncoimmunology

PREMIER AUTEURLecoester B

TITREMultidimensional immune profiling uncovers biphasic peripheral T-cell dynamics after chemoradiation in patients with locally advanced head and neck cancer.

ANNÉE2026

JOURNALOncoimmunology

PREMIER AUTEURTruntzer C

TITREPooled analysis of 2 clinical trials of first-line chemoimmunotherapy for metastatic microsatellite stable colorectal cancer MEDITREME and METIMMOX studies.

ANNÉE2026

JOURNALOncoimmunology

PREMIER AUTEURRébé C

TITREThe double face of IL-1β in lung cancer.

ANNÉE2026

JOURNALJournal of enzyme inhibition and medicinal chemistry

PREMIER AUTEURNannini S

TITREIn vitro screening of compounds for targeting gastric cancer with Y220C p53 mutation: a molecule combining zinc chelation and a Michael acceptor drives CDKN1 and BBC3 expression to restore a p53-dependent cytotoxicity.

ANNÉE2026

JOURNALOncology letters

PREMIER AUTEURSimon A

TITREEmergence of KRAS mosaicism with multiple variants during treatment with alectinib in ALK-positive metastatic non-small cell lung cancer: A case report.

ANNÉE2026

JOURNALMolecular therapy. Oncology

PREMIER AUTEURFauveau C

TITREDissecting residual disease in spheroids reveals pan-cancer persistence signatures and a therapeutic window for oncolytic viruses.

ANNÉE2026

JOURNALJournal of the Endocrine Society

PREMIER AUTEURJourné A

TITREGenetic factors associated with thymic tumors in patients with MEN1: a nested case-control study in the GTE/AFCE cohort.

ANNÉE2026

JOURNALThe Lancet. Oncology

PREMIER AUTEURHennequin C

TITREHigh-dose radiotherapy in patients with high-risk prostate cancers treated with long-term androgen deprivation therapy (GETUG AFU 18): a randomised, phase 3 trial.

Retrouvez aussi

Unités de recherche, établissements

Projets de recherche

Publications scientifiques